Frequency and Phenotype of Aquaporin-4-IgG and Coexistent Autoimmune Encephalitis Antibody Biomarkers
ObjectiveAims of this study were 1) to evaluate which autoimmune encephalitis autoantibodies can co-exist in patients with aquaporin-4-IgG (AQP4-IgG) and 2) what is the clinical phenotype of patients with AQP4-IgG+ and autoimmune encephalitis autoantibodies. BackgroundNeuromyelitis optica spectrum disorder (NMOSD) typically presents with optic neuritis, myelitis, or brainstem attacks. Rarely, patients can experience encephalopathy. NMOSD patients often have co-existent systemic autoimmunity. Design/MethodsTo ensure homogeneity in tests, the frequency of AQP4-IgG and autoimmune encephalitis antibodies association was evaluated on patients with AQP4-IgG+ tested for autoimmune encephalitis antibodies (2018- 2022). Then, we interrogated the Neuroimmunology laboratory database for AQP4-IgG+ patients (2007 to 2022, n=6,645) and identified patients with coexistent NMDA-R-IgG or GFAP-IgG. Clinical and radiological features of these patients were then compared to those of a control group of AQP4-IgG+ NMOSD from the clinical database. ResultsCoexistent neuronal/glial-IgGs were found in 1/128 (0.7%) sera and 21/126 (17%) cerebrospinal fluid tested. NMDA-R-IgG was the most frequent antibody detected in children (6/8 [80%], GFAP-IgG was the most common in adults (9/13 [69%]). We identified 21 AQP4-IgG+ with coexistent neuronal or glial antibodies and clinico-radiological data (9 isolated NMDA-R-IgG, 9 NMDA-R-IgG/GFAP-IgG, 2 isolated GFAP-IgG, and 1 NMDA-R-IgG/MOG-IgG). Compared to 311 AQP4-IgG+NMOSD in the clinical database, those with coexistent neuronal/glial antibodies had a higher frequency of encephalopathy, ovarian tumors, temporal lobe, basal ganglia and diencephalic involvement (all p<0.001). ConclusionsAQP4-IgG can rarely coexist with autoimmune encephalitis autoantibodies, especially with NMDA-R-IgG and GFAP-IgG. These patients usually have features of autoimmune encephalitis, and several had ovarian teratoma.
Authors
- Amy Kunchok (ORCID: https://orcid.org/0000-0002-8387-6491)
- Thomas Shoemaker (ORCID: https://orcid.org/0000-0002-1085-6860)
- Jacqueline Nicholas (ORCID: https://orcid.org/0000-0002-6328-1941)
- Αναστασία Ζεκερίδου (ORCID: https://orcid.org/0000-0002-1960-9065)
- Laura Cacciaguerra (ORCID: https://orcid.org/0000-0001-9342-2410)
- Eoin P. Flanagan (ORCID: https://orcid.org/0000-0002-6661-2910)
- Emmanuelle L. Waubant (ORCID: https://orcid.org/0000-0001-5188-0157)
- Wendy G. Mitchell (ORCID: https://orcid.org/0000-0001-8082-1383)
- Kurt Sieloff
- Vanessa Sui
- Andrew B. McKeon (ORCID: https://orcid.org/0000-0001-6856-8143)
- Karen S. Fernández (ORCID: https://orcid.org/0000-0002-0097-9293)
- William Meador
- Nusrat Ahsan (ORCID: https://orcid.org/0000-0002-3502-8658)
- Shruti Agnihotri (ORCID: https://orcid.org/0000-0002-2461-0255)
- Binxia Yang
- Amy May Lin Quek
- Erin McLeod
- Sean J Pittock
Publication Details
- Journal
- Neurology
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1212/01.wnl.0001051696.89300.fd
- Primary Topic
- Autoimmune Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense